Novo Nordisk A/S, Blackstone, Apollo Global Management, BlackRock, Prologis, SpringWorks Therapeutics, and Welltower are the seven Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to deliver above-average revenue and earnings growth compared with the overall market. These companies typically reinvest their profits into expanding operations rather than paying dividends, which can drive higher share-price multiples. Because much of their valuation hinges on future performance, growth stocks can offer substantial upside but also carry greater volatility. These companies had the highest dollar trading volume of any Growth stocks within the last several days.
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NYSE NVO traded down $1.93 during midday trading on Thursday, reaching $65.62. 8,714,853 shares of the stock traded hands, compared to its average volume of 6,305,720. The company's 50 day moving average is $70.14 and its 200 day moving average is $86.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The stock has a market capitalization of $294.47 billion, a PE ratio of 19.95, a P/E/G ratio of 0.90 and a beta of 0.65.
Read Our Latest Research Report on NVO
Blackstone (BX)
Blackstone Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services.
Shares of BX stock traded up $4.24 on Thursday, reaching $140.38. 1,897,117 shares of the company's stock were exchanged, compared to its average volume of 3,759,165. The stock has a market capitalization of $102.43 billion, a PE ratio of 38.67, a P/E/G ratio of 1.07 and a beta of 1.67. Blackstone has a 52 week low of $115.66 and a 52 week high of $200.96. The company has a current ratio of 0.67, a quick ratio of 0.71 and a debt-to-equity ratio of 0.61. The company's fifty day simple moving average is $137.46 and its 200 day simple moving average is $162.68.
Read Our Latest Research Report on BX
Apollo Global Management (APO)
Apollo Global Management, Inc. is a private equity firm specializing in investments in credit, private equity, infrastructure, secondaries and real estate markets. The firm prefers to invest in private and public markets. The firm's private equity investments include traditional buyouts, recapitalization, distressed buyouts and debt investments in real estate, corporate partner buyouts, distressed asset, corporate carve-outs, middle market, growth, venture capital, turnaround, bridge, corporate restructuring, special situation, acquisition, and industry consolidation transactions.
NYSE APO traded up $4.25 on Thursday, reaching $133.59. 1,925,508 shares of the stock traded hands, compared to its average volume of 3,853,905. The company has a fifty day moving average price of $132.15 and a 200-day moving average price of $152.64. Apollo Global Management has a 12 month low of $95.11 and a 12 month high of $189.49. The company has a market cap of $76.21 billion, a price-to-earnings ratio of 18.28, a PEG ratio of 1.17 and a beta of 1.67. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 1.44.
Read Our Latest Research Report on APO
BlackRock (BLK)
BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks.
Shares of BLK traded up $20.24 during midday trading on Thursday, hitting $940.60. 241,111 shares of the company's stock traded hands, compared to its average volume of 684,154. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.45. BlackRock has a 1 year low of $752.30 and a 1 year high of $1,084.22. The stock has a market capitalization of $146.03 billion, a price-to-earnings ratio of 22.40, a price-to-earnings-growth ratio of 1.90 and a beta of 1.41. The firm's fifty day moving average is $914.30 and its 200-day moving average is $979.54.
Read Our Latest Research Report on BLK
Prologis (PLD)
Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries.
Shares of NYSE PLD traded up $1.14 during midday trading on Thursday, reaching $106.18. The company had a trading volume of 1,555,894 shares, compared to its average volume of 4,139,151. The company has a current ratio of 0.75, a quick ratio of 0.43 and a debt-to-equity ratio of 0.53. The business's 50-day simple moving average is $106.61 and its 200 day simple moving average is $111.60. Prologis has a 1 year low of $85.35 and a 1 year high of $132.57. The stock has a market cap of $98.53 billion, a P/E ratio of 26.55, a P/E/G ratio of 2.70 and a beta of 1.25.
Read Our Latest Research Report on PLD
SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
SpringWorks Therapeutics stock traded down $0.03 during trading hours on Thursday, hitting $46.18. 2,622,777 shares of the stock traded hands, compared to its average volume of 1,969,720. The firm's 50 day moving average price is $44.60 and its 200-day moving average price is $41.36. The stock has a market capitalization of $3.46 billion, a price-to-earnings ratio of -13.27 and a beta of 0.77. SpringWorks Therapeutics has a 1 year low of $28.21 and a 1 year high of $62.00.
Read Our Latest Research Report on SWTX
Welltower (WELL)
Welltower Inc. NYSE: WELL, a real estate investment trust ("REIT") and S&P 500 company headquartered in Toledo, Ohio, is driving the transformation of health care infrastructure. Welltower invests with leading seniors housing operators, post-acute providers and health systems to fund the real estate infrastructure needed to scale innovative care delivery models and improve people's wellness and overall health care experience.
NYSE WELL traded down $1.54 during trading hours on Thursday, reaching $149.80. The stock had a trading volume of 729,424 shares, compared to its average volume of 2,883,077. Welltower has a 52-week low of $97.22 and a 52-week high of $158.55. The stock has a fifty day moving average of $148.01 and a 200 day moving average of $139.49. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.22 and a current ratio of 4.22. The stock has a market cap of $97.96 billion, a P/E ratio of 96.03, a price-to-earnings-growth ratio of 2.87 and a beta of 0.94.
Read Our Latest Research Report on WELL
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
